Bristol-Myers Squibb has got its $14 billion acquisition of Karuna Therapeutics over the line, having had to withdraw and refile antitrust paperwork and contend with a shareholder lawsuit that tried ...

Bristol-Myers Squibb has decided to gamble on the FDA approving Karuna Therapeutics’ schizophrenia drug candidate KarXT next year, agreeing to buy the company for approximately $14 billion. The ...

Got a confidential news tip? We want to hear from you. Sign up for free newsletters and get more CNBC delivered to your inbox Get this delivered to your inbox, and ...

Are the NFL, NBA doing enough to combat tanking? A Division of NBCUniversal. DISCLAIMER: This site and the products offered are for entertainment purposes only, and there is no gambling offered on ...

From Baltimore to Loyola to Northwestern to Germany to Santa Cruz to DubNation, Pat Spencer's journey is defined by determination. Postgame Warriors Talk: Draymond Green - 02/05/2026 Postgame Warriors ...

These undervalued stocks with wide economic moats and consistent cash flows look attractive.